A new BristolMyers Squibb Co drug helped skincancer patients live longer than those who received chemotherapy in a clinical trial the latest evidence behind a promising new crop of drugs that work by unleashing the bodys immune system against tumors It is the first time a latestage clinical trial has shown that one of a new class of drugswhich block an immunecell component known as PDimprove patient survival compared to a comparator drug Previous clinical results for the Bristol drug and similar drugs from Merck
  